Market Trends of Proton Pump Inhibitors Industry
The Esomeprazole Segment is Expected to Account for a Significant Share Over the Forecast Period
Esomeprazole is expected to have a significant share of the revenue as it is mostly indicated to treat the symptoms of GERD, heartburn, and other disorders involving excessive stomach acids. The shift from being a prescription-only drug to being sold as an over-the-counter (OTC) drug is likely to be a major driving force for the sales of the drug shortly.
In addition, major market players are focused on research and development and market expansion activities to bring new and reliable formulations to the market. For instance, in August 2021, the Subject Matter Expert Committee (SEC) functioning under CDSCO recommended Sun Pharma conduct a phase 3 clinical trial of esomeprazole dual-release gastro-resistant tablets 80mg vs esomeprazole gastro-resistant tablets 40mg bids for the proposed indication.
Additionally, the strategic initiatives taken by the market players are propelling the growth of the segment. For instance, in March 2021, Daiichi Sankyo Co., Ltd. transferred the marketing and distribution rights for the proton pump inhibitor Nexium capsules 10 mg and 20 mg and Nexium granules for suspension 10 mg and 20 mg (esomeprazole magnesium) to AstraZeneca in Japan.
Thus, owing to all the above-mentioned factors, the Esomeprazole segment is expected to achieve high growth rates.
North America is Expected to Account for A Significant Share of the Market
North America currently dominates the proton pump inhibitors market and is anticipated to show a similar trend over the forecast period without significant fluctuations. There is a rising burden of GERD in the United States, Canada, and Mexico due to people's shift toward unhealthy lifestyles. According to an article published by the journal of annals of esophagus in March 2022, it is estimated that 40% of the United States population experience GERD symptoms, and 10-20% of people are being affected on a weekly basis.
In the United States, proton pump inhibitors are one of the most widely prescribed drugs, and increased PPI use has been observed in United States ambulatory settings for the last few years. Furthermore, many firms are spending heavily on promoting their brands. The widespread use of PPIs has also gained the attention of the American Board of Internal Medicine; as a result, the board conducted a campaign to promote the appropriate use of PPIs.
Moreover, product launches in generic categories are also expected to impact the market. For instance, in February 2021, Dr. Reddy's Laboratories Ltd. launched lansoprazole DR, orally disintegrating tablets, a therapeutic equivalent generic version of Prevacid soluTab delayed-release orally disintegrating tablets, 15 mg and 30 mg, approved by the United States Food and Drug Administration (USFDA). Such generic drug launches are also propelling the growth of the market.
Thus, owing to the abovementioned factors, the proton pump inhibitor market in the North American region is expected to project growth over the forecast period.
